Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease.
作者信息
Liendo-Martínez Katiuska Herminia, Baratech-Calpena Francisco Javier, Ji Zichen, Pedraza-Serrano Fernando, Caballero-Segura Francisco José, de Miguel-Díez Javier
机构信息
Respiratory Department, Gregorio Marañón General University Hospital, 28007 Madrid, Spain.
Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain.
出版信息
Open Respir Arch. 2023 Sep 18;5(4):100268. doi: 10.1016/j.opresp.2023.100268. eCollection 2023 Oct-Dec.
Abstract
摘要
相似文献
1
Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease.
Open Respir Arch. 2023 Sep 18;5(4):100268. doi: 10.1016/j.opresp.2023.100268. eCollection 2023 Oct-Dec.
2
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
Pulm Pharmacol Ther. 2021 Dec;71:102099. doi: 10.1016/j.pupt.2021.102099. Epub 2021 Nov 15.
3
Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
Respiration. 2021;100(9):923-932. doi: 10.1159/000515607. Epub 2021 May 5.
4
Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits?
Adv Respir Med. 2021;89(2):231-233. doi: 10.5603/ARM.a2021.0023.
5
Antifibrotics in systemic sclerosis.
Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101671. doi: 10.1016/j.berh.2021.101671. Epub 2021 Apr 7.
6
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review.
Eur Respir Rev. 2021 Jun 1;30(160). doi: 10.1183/16000617.0050-2021. Print 2021 Jun 30.
7
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Adv Ther. 2021 Jan;38(1):268-277. doi: 10.1007/s12325-020-01523-7. Epub 2020 Oct 24.
8
Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
J Clin Med. 2021 May 25;10(11):2285. doi: 10.3390/jcm10112285.
9
Safety data from the use of antifibrotics in connective tissue disease-related interstitial lung disease: particular emphasis on association with immunosuppression.
ARP Rheumatol. 2023 Jan-Mar;2(1):88-91. Epub 2023 Jan 14.
10
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
BMC Pulm Med. 2019 Nov 12;19(1):213. doi: 10.1186/s12890-019-0937-0.
本文引用的文献
1
Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study.
Life (Basel). 2023 Feb 10;13(2):483. doi: 10.3390/life13020483.
2
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
3
Idiopathic pulmonary fibrosis: Current and future treatment.
Clin Respir J. 2022 Feb;16(2):84-96. doi: 10.1111/crj.13466. Epub 2022 Jan 10.
4
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
Respir Res. 2021 Feb 24;22(1):66. doi: 10.1186/s12931-021-01643-w.
5
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.
Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798. Epub 2020 Dec 24.
6
Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.
PLoS One. 2020 Jan 30;15(1):e0228390. doi: 10.1371/journal.pone.0228390. eCollection 2020.
7
Idiopathic Pulmonary Fibrosis.
N Engl J Med. 2018 May 10;378(19):1811-1823. doi: 10.1056/NEJMra1705751.
8
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15.
9
Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).
Arch Bronconeumol. 2013 Sep;49(9):388-401. doi: 10.1016/j.arbres.2013.04.001. Epub 2013 May 28.
10
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
Zotero 插件